VCA Stocks

Auspex Pharmaceuticals Inc., a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced a $13.875 million Series B financing.  Auspex Pharmaceuticals, founded in 2001, is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs. For more than five years the company has worked to apply its targeted deuteration strategy to drug molecules across multiple therapeutic areas, secure a proprietary position on several hundred compounds and initiate development on multiple clinical candidates. Auspex believes its approach can rapidly generate potential best-in-class therapeutics for significant markets, while reducing the time, cost and risk of drug development.